United Therapeutics Corporation (UTHR) - Stock Analysis
Last updated: Apr 5, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Multiple March Phase 3 wins (ralinepag ADVANCE OUTCOMES, positive TETON‑1 Tyvaso data) plus a just‑launched $2.0B buyback with a $1.5B ASR executed on 2026‑03‑09 and strong FY2025 revenue/FCF have driven a +16.9% 21‑day ROC and price ~10% above its 21‑day SMA; this combination of fresh clinical catalysts, aggressive capital return and strong technical momentum supports continued upside over the coming sessions.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Very high margins • Strong liquidity • Large buyback outflows UTHR is a highly profitable, cash‑generative, low‑debt company with exceptional liquidity and margins but carries rich valuation and material share‑buyback/distribution outflows that trimmed net cash.
Price Behavior
Key Price Behavior Insights: • Short-term uptrend • Consolidation support • Elevated volatility Support Level: $520–$535 Resistance Level: $588–$593 UTHR is in a short-term uptrend—up ~16.5% from ~$485 to ~$565 over the last month, trading above the last month SMA (~$536) and back above the $520–$535 consolidation (support), while facing resistance near $588–$593 and elevated intraperiod volatility that could prompt mean reversion.
Sentiment & News
Key News Insights: • TETON-1 efficacy • Large buybacks • Insider selling United Therapeutics surged on compelling Phase III Tyvaso (TETON) IPF results, a $3.5B capital-return package and rising institutional buying, offset by insider sales and cautious estimate revisions.
AI Summary
United Therapeutics has shifted from a single‑product PAH cash generator to a high‑leverage commercial-growth story driven by Tyvaso's potential IPF expansion and an outcomes‑proven ralinepag franchise, materially increasing addressable market and re-rating upside; however, the company's aggressive $1.5B ASR/buyback cadence meaningfully accelerates cash depletion and concentrates downside on timely regulatory approvals, payer uptake, and commercial execution. Monitor early IPF launch metrics (prescriber adoption, payer coverage, and initial revenue cadence) and quarterly FCF against buyback pace—if rollout lags or FCF misses, downside risk is amplified.
Description
United Therapeutics is a biopharmaceutical company that develops and markets therapies for chronic and life‑threatening conditions, with a primary emphasis on pulmonary hypertension and select oncology indications. Its commercial portfolio includes injectable, inhaled and oral prostacyclin‑based treatments for pulmonary arterial hypertension and an antibody therapy for high‑risk neuroblastoma, while its development pipeline comprises inhalation devices, a wearable drug pump, oral agents, gene therapy and ongoing clinical programs in related pulmonary disorders. The company maintains strategic collaborations for device and drug development and is based in Silver Spring, Maryland, where it was incorporated in 1996.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 31 | Apr 7 | UTHR | United Therapeutics Corporation | Multiple March Phase 3 wins (ralinepag ADVANCE OUTCOMES, positive TETON‑1 Tyvaso data) plus a just‑launched $2.0B buyback with a $1.5B ASR executed on 2026‑03‑09 and strong FY2025 revenue/FCF have driven a +16.9% 21‑day ROC and price ~10% above its 21‑day SMA; this combination of fresh clinical catalysts, aggressive capital return and strong technical momentum supports continued upside over the coming sessions. | Closed | -4.6% |
| Mar 13 | Mar 20 | UTHR | United Therapeutics Corporation | Strong near‑term setup: large capital return (up to $2B buyback and $1.5B ASR started 2026-03-09), two positive Phase 3 readouts in March (ralinepag ADVANCE OUTCOMES 2026-03-02 and nebulized Tyvaso TETON‑2 NEJM IPF data 2026-03-11), record FY2025 revenue and >40% net margin, plus ~+13.5% price move into mid‑March. Combination of active repurchases, de‑risked pipeline and technical breakout supports continued upside over the next few days, albeit with biotech volatility. | Closed | -2.2% |